Skip to main content
. 2006 May 6;136(1):65–70. doi: 10.1016/j.jviromet.2006.03.030

Fig. 3.

Fig. 3

CPV-2 DNA titres measured by the TaqMan assay and the type 2/variants MGB probe assay. The type 2-based vaccines marketed in Italy (a) and 30 field samples tested positive to types 2a (n = 10), 2b (n = 10) or 2c (n = 10) (b) and covering the shared log10 dynamic ranges of the assays were analysed. DNA titres are expressed as copy numbers per dose and per mg of faeces for vaccines and field samples, respectively.